Navigation Links
Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
Date:4/7/2009

GAITHERSBURG, Md., April 7 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. and Danisco BioActives announced today that they have signed a partnering agreement for the development of a new biologic drug candidate, which may help to prevent a deadly disease called necrotizing enterocolitis (NEC).

NEC is a rare, life-threatening gastrointestinal disorder in infants that affects very low birth weight (VLBW) premature infants (babies less than 1,500 grams or 3 pounds, five ounces). There are approximately 60,000 VLBW babies born each year in the United States, of which 5 percent to 15 percent will acquire NEC. Treatment options for this condition are extremely limited and mortality rates of 20 percent to 30 percent have gone unchanged in the United States for more than 30 years.

Under the terms of the agreement, Sigma-Tau and Danisco will collaborate to develop STP-206, a biologic agent comprised of live bacteria, which may be effective in preventing the occurrence of NEC. Sigma Tau will manage the clinical development of the product and, ultimately, will seek the approval of the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) to market the drug for the prevention of NEC. Human clinical trials are scheduled to start later this year.

"We have had a very longstanding and successful relationship with Danisco and we are very pleased to move forward with this agreement," said Gregg Lapointe, chief executive officer of Sigma-Tau Pharmaceuticals. "Together, we hope to provide a new and innovative option to prevent this deadly disease and ultimately save lives."

"Danisco is excited to collaborate with Sigma-Tau Pharmaceuticals in the development of an innovative live biotherapeutic solution to this complex and life-threatening disorder," said Scott Bush, dietary supplements vice president for Danisco BioActives.

About Necrotizing Ent
'/>"/>

SOURCE Sigma-Tau Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
2. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
3. Sigma-tau HealthScience Launches www.GlycoCarn.com
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... Newport Beach, CA (PRWEB) November 23, 2014 ... founder of American Medical Aesthetics & Wellness was ... Dr. Asher Milgrom, Ph.D. is president and CEO of ... Skincare. Dr. Asher Milgrom received a full scholarship ... Sciences and the Medical School at the University of ...
(Date:11/23/2014)... Syngenta lawsuits are now being investigated ... and agribusinesses that have allegedly incurred significant financial damages ... and Agrisure Duracade, genetically modified (GMO) corn seed ... in China. According to a report from Bloomberg News, ... corn imports. Because China is the third-largest American corn ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3
... of using plant hormones to fight cancer cells. Plant need ... cuttings grow roots. Scientists at the Cancer Research Campaign (CRC), ... kill cancer cells. , Indole ... IAA are added with an enzyme, toxic by products, which ...
... itself by growing new cells after a heart attack. This ... Italy. Dr. Piero Anversa and colleagues of the New York ... called myocytes continued to divide after a heart attack. ... the hearts of 13 people who died within a few ...
... disease, that requires insulin injections daily. Researchers are slowly ... Some medical research centers in the U.S. and Europe ... by transplanting insulin-producing islet cells combined with less toxic ... lives without insulin. , A.M. ...
... size of children's tummies may offer a simple method of ... diabetes at a later age.Among adults, fat around the waist ... studies suggest that it is a better indicator of risk ... ,A large waist is said to be associated ...
... the brain and its function has always left man ... puzzle, some key factors// have been identified that could ... in premature babies and hence help treat prematurity. ... also prevent brain damage repair in neurological diseases like ...
... drinking coffee could decrease the risk of liver cancer.Researchers ... showed self-reported frequency of coffee consumption among more than ... researchers say they found that those who drink coffee ... while those drinking one or more cups a day ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... BETHESDA, Md., Nov. 1, 2011   For the first ... cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review ... approval in 2012. This milestone comes as the largest ... Anaheim, Calif., Nov. 3 – 5, 2011. ...
... the world,s leading provider of centralized expert assessments in ... disorders, announced it has been selected as one of ... NJBIZ, New Jersey,s premiere business news publication, annually identifies ... New Jersey,s most dynamic companies who progressively contribute to ...
Cached Medicine Technology:Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care 2MedAvante Is One of NJ's Fastest Growing Companies 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: